If you take Xarelto and you are hoping a cheaper generic has finally arrived, the honest answer is: it depends entirely on your dose, and for most people the generic does not yet apply. A generic version of rivaroxaban (the active ingredient in Xarelto) does exist as of 2025 — but only as a 2.5 mg tablet, and only for a specific use. SunnyPharma built this guide from FDA, CMS, and manufacturer sources to explain exactly which dose has a generic, why the others don’t, and the routes that actually lower your cost in the meantime.
The short version: if you take Xarelto for atrial fibrillation, DVT, or a pulmonary embolism, your dose is almost certainly 10, 15, or 20 mg — and there is no generic for those yet. The 2.5 mg generic is for a different purpose. So the path to a lower price runs through the Medicare-negotiated price, manufacturer assistance, or a savings card, not the pharmacy generic shelf. For any decision about your dose or treatment, your clinician is the right source.
- Only the 2.5 mg dose has a generic — approved March 2025 (Lupin, Taro)
- The 2.5 mg is for CAD/PAD only, not the AFib/DVT/PE doses
- 10, 15, and 20 mg remain brand-only — patent-protected on once-daily dosing beyond 2025
- No announced date for a generic of the higher doses
- What lowers cost now: the Medicare-negotiated $197 price, patient assistance, or the commercial savings card
- Never switch your dose to chase a generic — and never stop Xarelto over cost (boxed warning: clot/stroke risk)
Which Xarelto Dose Has a Generic?
Here is the distinction that resolves almost every question about a Xarelto generic. The FDA approved the first generic rivaroxaban in March 2025 — but it cleared only the 2.5 mg tablet, made by Lupin and by Taro (a Sun Pharma subsidiary). And the 2.5 mg dose is approved for a narrower set of conditions than the ones most Xarelto patients take it for.
| Dose | Used for | Generic available? |
|---|---|---|
| 2.5 mg | Coronary artery disease (CAD) and peripheral artery disease (PAD), usually with aspirin | ✅ Yes — approved March 2025 |
| 10 mg | Preventing blood clots after hip or knee surgery; some long-term VTE prevention | ❌ No — brand-only |
| 15 mg | Atrial fibrillation; treating DVT and PE (with food) | ❌ No — brand-only |
| 20 mg | Atrial fibrillation; treating DVT and PE (with food) | ❌ No — brand-only |
So if you were prescribed Xarelto for an irregular heartbeat (AFib) or for a clot in your leg or lung, you are on a 15 or 20 mg dose, and there is no generic for it. The 2.5 mg generic that made headlines does not apply to you.
Do not switch your dose to get the generic. The 2.5 mg generic is not a cheaper version of your 20 mg tablet — it is a different strength for a different condition. Taking it in place of your prescribed dose would leave you under-treated and at risk of a clot. The generic price is irrelevant unless 2.5 mg is genuinely your prescribed dose.
Why Only the 2.5 mg Dose Went Generic
It comes down to patents. Xarelto is developed and sold by Johnson & Johnson (through its Janssen division) together with Bayer. The 2.5 mg tablet’s protection lapsed enough for the FDA to approve generic competition in early 2025. But according to Bayer, the 10, 15, and 20 mg tablets are protected by a patent on once-daily dosing that runs beyond 2025 — so generic manufacturers are legally blocked from selling those strengths even though the FDA framework for generics exists.
That is why one manufacturer, Janssen, still supplies essentially all of the higher-dose Xarelto in the country. There is no announced date for when a generic of the 10, 15, or 20 mg doses will arrive; it depends on patent litigation and FDA review, neither of which moves on a public schedule.
What Xarelto Costs — and How to Lower It Without a Generic
Since most patients can’t use the generic, the real question is how to bring down the cost of brand-name Xarelto. The good news is that 2026 brought a major change for Medicare beneficiaries.
The routes that actually lower your cost
- Medicare beneficiaries — the negotiated price: Xarelto was one of the first drugs with a Medicare-negotiated price under the Inflation Reduction Act. A price of $197 for a 30-day supply took effect January 1, 2026. That is what the government pays; your copay is set by your Part D plan, but your total Part D out-of-pocket is capped at $2,100 for the year.
- Uninsured — manufacturer patient assistance: The Johnson & Johnson Patient Assistance Foundation, through Janssen CarePath, provides Xarelto at no cost to qualifying patients who are uninsured or underinsured and meet income limits (typically up to a set percentage of the federal poverty level).
- Commercially insured — the savings card: The Xarelto withMe Savings Card can reduce your copay to as little as $0–$10 per fill. It is for private insurance only and cannot be used with Medicare, Medicaid, or other government coverage.
- Discuss alternatives with your clinician: If cost is a real barrier, a clinician can discuss whether a different anticoagulant with a full generic line — such as another factor Xa inhibitor or warfarin — is appropriate for you. That is a clinical decision, not a do-it-yourself swap.
Never stop taking Xarelto because of cost. Xarelto carries an FDA boxed warning that stopping it early raises the risk of blood clots and stroke. If you cannot afford it, talk to your clinician or pharmacist before skipping or stopping doses — one of the pathways above almost always fits, and a clinician can discuss a lower-cost anticoagulant rather than leaving you untreated.
Is the Generic as Good as Brand-Name Xarelto?
For the dose it covers, yes. An FDA-approved generic must contain the same active ingredient, be absorbed the same way (bioequivalence), and meet the same manufacturing-quality standards as the brand. Generic rivaroxaban 2.5 mg is therefore a genuine equal substitute for Xarelto 2.5 mg for its approved CAD and PAD uses — there is no quality compromise. The only limitation is which strengths are available, not how well they work. So patients who legitimately take the 2.5 mg dose can switch with confidence; everyone else is waiting on availability, not quality.
Related Anticoagulant Guides
For the bigger picture on anticoagulant costs and the coupon question, start with the hub or the Eliquis cost guides.
Frequently Asked Questions
Is there a generic for Xarelto?
Partly. The FDA approved the first generic rivaroxaban in March 2025, but only the 2.5 mg tablet, and only for coronary artery disease (CAD) and peripheral artery disease (PAD). The 10 mg, 15 mg, and 20 mg doses used for atrial fibrillation, DVT, and PE remain brand-only, because Johnson & Johnson and Bayer hold patent protection on the once-daily dosing of those strengths beyond 2025. So most people taking Xarelto cannot yet switch to a generic, and need other ways to lower cost.
Why is only the 2.5 mg dose of Xarelto available as a generic?
The 2.5 mg tablet covers a different, narrower use than the higher doses. It is approved to reduce the risk of major cardiovascular events in coronary artery disease and major thrombotic vascular events in peripheral artery disease, usually taken with aspirin. The 10, 15, and 20 mg doses, used for stroke prevention in atrial fibrillation and for treating DVT and PE, are protected by separate patents on once-daily dosing that extend beyond 2025, so generic makers cannot yet sell those strengths.
Can I switch to generic rivaroxaban to save money?
Only if you take the 2.5 mg dose for coronary or peripheral artery disease. If you take Xarelto 10, 15, or 20 mg for atrial fibrillation, DVT, or PE, there is no generic version of your dose, and substituting the 2.5 mg generic is not appropriate because it is a different strength for a different purpose. Never change your dose to chase a generic price. If cost is the issue, the better routes are the Medicare-negotiated price, manufacturer patient assistance, or a commercial savings card.
How much does Xarelto cost in 2026?
Without insurance, brand-name Xarelto runs roughly $500 to $650 per month. For Medicare beneficiaries, a Medicare-negotiated price of $197 for a 30-day supply took effect January 1, 2026 — about a 62% cut from the prior list price, because Xarelto was one of the first drugs negotiated under the Inflation Reduction Act. That figure is what the government pays; your actual out-of-pocket depends on your Part D plan, and your total Part D out-of-pocket is capped at $2,100 for the year in 2026.
When will a generic for Xarelto 20 mg be available?
No date has been announced. The 10, 15, and 20 mg strengths are protected by patents on once-daily dosing that Bayer and Johnson & Johnson hold beyond 2025, and the timeline for a generic of those strengths depends on patent litigation and FDA review. Until that resolves, the reliable ways to lower cost on the higher Xarelto doses are the Medicare-negotiated price, manufacturer patient assistance for the uninsured, and a commercial savings card for the privately insured.
How can I get Xarelto for free or low-cost if there’s no generic for my dose?
If you are uninsured or underinsured and meet income limits, the Johnson & Johnson Patient Assistance Foundation, through Janssen CarePath, provides Xarelto at no cost to qualifying patients. If you have commercial insurance, the Xarelto withMe Savings Card can lower your copay to as little as $0 to $10 per fill — but it cannot be used with Medicare, Medicaid, or other government insurance. Medicare beneficiaries instead rely on the negotiated price, the Part D out-of-pocket cap, and Extra Help if their income qualifies.
Is generic rivaroxaban as good as brand-name Xarelto?
Yes, for the dose it covers. An FDA-approved generic must contain the same active ingredient, work the same way in the body, and meet the same quality and bioequivalence standards as the brand. Generic rivaroxaban 2.5 mg is therefore an equal substitute for Xarelto 2.5 mg for its approved CAD and PAD uses. The only limitation is availability of strength, not quality — there simply is no generic for the higher doses yet.
What happens if I stop taking Xarelto because of cost?
Stopping Xarelto because of cost is dangerous. Xarelto carries an FDA boxed warning that stopping it early raises the risk of blood clots and stroke. If cost is the barrier, talk to your clinician or pharmacist before skipping or stopping doses, and use the cost pathways first: the Medicare-negotiated price, the Part D out-of-pocket cap, manufacturer patient assistance, or a commercial savings card. A clinician can also discuss whether a different, lower-cost anticoagulant — such as a generic option — is appropriate rather than going without treatment.
How we reviewed this article:
SunnyPharma follows strict sourcing guidelines and relies on government agencies (FDA, CMS/Medicare) and official manufacturer program documentation. Dr. Swiggum’s review covers the clinical content; cost, coverage, and generic-status details are drawn from FDA, CMS, and manufacturer sources. We use only credible, verifiable sources to ensure accuracy.
Reviewer disclosure: Dr. Swiggum has disclosed financial relationships with Boehringer Ingelheim, Eli Lilly, Novartis, Novo Nordisk, Pfizer, and GSK, including work related to dabigatran, an anticoagulant that competes with the medication discussed here. Her review is limited to clinical accuracy and does not involve SunnyPharma’s editorial or cost-pathway recommendations.
Read our editorial policy →Sources & References
- FDA — Xarelto (rivaroxaban) Prescribing Information (boxed warning, indications by dose): accessdata.fda.gov
- FDA — first generic rivaroxaban 2.5 mg approval (CAD/PAD), March 2025: fda.gov
- Medicare — Drug Price Negotiation Program (Xarelto negotiated price effective 2026): cms.gov
- CMS — Draft CY 2026 Part D Redesign Program Instructions Fact Sheet (annual out-of-pocket threshold $2,100): cms.gov
- Medicare.gov — Costs for Medicare drug coverage (Part D) and the out-of-pocket cap: medicare.gov
- Johnson & Johnson Patient Assistance Foundation (Xarelto, uninsured patients): jjpaf.org
- Xarelto — official patient site and withMe Savings Card (Janssen): xarelto-us.com
- HHS Office of Inspector General — copay coupons and the federal anti-kickback statute: oig.hhs.gov
- NIH MedlinePlus — Rivaroxaban: medlineplus.gov
- FDA — Generic drugs: questions & answers (bioequivalence standards): fda.gov